Suwon, South Korea

Nam-Jin Park

This inventor holds 1 USPTO granted patent. Top assignee: Yuhan Corporation. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nam-Jin Park. Retrieved from https://idiyas.com/inventor/nam-jin-park-tib02ir5

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Nam-Jin Park

Introduction

Nam-Jin Park is a notable inventor based in Suwon, South Korea. He has made significant contributions to the field of chemistry, particularly in the preparation of ribofuranose derivatives. His work is essential for the development of important pharmaceutical compounds.

Latest Patents

Nam-Jin Park holds a patent for "Processes for preparing β-D-ribofuranose derivatives." This patent outlines a method for synthesizing these derivatives, which serve as intermediates in the production of ribavirin. The process is characterized by its mild conditions and the use of specific catalysts, including methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. He has 1 patent to his name.

Career Highlights

Nam-Jin Park is currently employed at Yuhan Corporation, a leading pharmaceutical company in South Korea. His role involves research and development, where he applies his expertise in organic chemistry to innovate new processes and products.

Collaborations

Throughout his career, Nam-Jin Park has collaborated with esteemed colleagues, including Tai-Au Lee and Ja-Heouk Khoo. These partnerships have fostered a productive environment for scientific exploration and innovation.

Conclusion

Nam-Jin Park's contributions to the field of chemistry and his innovative patent work highlight his importance as an inventor. His efforts continue to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…